The US health regulator has provided its approval to the drug firm Claris Lifesciences for generic anesthetic Bupivacaine injection.
Claris Lifesciences has said in a BSE filing that the company has got approval from the United States Food and Drug Administration (USFDA) for generic “Bupivacaine hydrochloride in 8.25 percent dextrose injection USP 7.5 mg/mL, single dose ampules with 2 ml fill volumes.”
Claris Lifesciences has said that with this approval, the company has 15 approvals and 25 under approval abbreviated new drug applications (ANDAs).
It further said that the company expects more product approvals during the year.
